Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Crucell« Terug naar discussie overzicht

$$$ CRUCELL H2 2007 $$$

9.827 Posts
Pagina: «« 1 ... 208 209 210 211 212 ... 492 »» | Laatste | Omlaag ↓
  1. [verwijderd] 7 november 2007 16:44
    07/11/2007 - Sanofi Pasteur has kicked off Phase II trials of its cell culture-based seasonal flu vaccine in the US, part of a five year project with the US Department of Health and Human Services (HHS).

    The French firm announced the initiation of the Phase II trials earlier today, following on from Phase I studies started in September last year.

    The vaccine is based on Dutch firm Crucell's popular PER.C6 cell line, which has proved promising in terms of developing an effective cell based vaccine that can be manufactured on a commercial scale.

    The cell culture flu vaccine project is part of a five year $97m contract with the HHS awarded back in 2005. The deal fired up Sanofi Pasteur's cell-based flu vaccine programme and brought the project towards the centre of the company's development plans.

    With plans pushing on, a recent R&D update by parent company Sanofi Aventis had regulatory submission for the vaccine scheduled for 2010.

    This fits squarely in with the five year timescale of the HHS contract, which comprised three main development branches for Sanofi to pursue: acceleration of cell-based flu vaccine plans (with Phase III trials to be underway by the end of 2008); creation and design of a manufacturing process to produce the vaccine in large quantities; and preparation of a feasibility plan to establish a cell culture vaccine production facility.

    Crucell's PER.C6 cell line has helped the company fulfil two of these criteria, with the production scale potential of the cell line demonstrated in a successful bioreactor run of 20,000 litres, showing its potential for commercial scale manufacturing of the flu shot.

    Sanofi used the services of the biologics arm of Swiss firm Lonza to achieve the scale-up process for the vaccine.

    The US-based facility for which Sanofi will present a feasibility study will be designed to supply 300 million doses of monovalent flu vaccine annually.

9.827 Posts
Pagina: «« 1 ... 208 209 210 211 212 ... 492 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.